Physician profile
Laurie E Mickle
NPI 1194779744
$1,874.07
in general payments reported to CMS, 2019-2025
25 companies · $283 in 2025
The $283 reported for 2025 was more than what 83% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $65.07 · 2022: $166 · 2023: $485 · 2024: $561 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,328.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $592.23 | 2022-2025 | Azstarys |
| Novo Nordisk INC | $240.87 | 2019-2025 | Wegovy |
| Lilly USA, LLC | $191.69 | 2019-2025 | Trulicity, Mounjaro, Zepbound |
| Amgen INC. | $148.13 | 2022-2025 | Repatha, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $107.19 | 2023-2024 | Rexulti, Abilify Maintena |
| Dexcom, INC. | $77.49 | 2022-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $58.58 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $46.56 | 2023-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $44.36 | 2019 | |
| Abbott Laboratories | $43.88 | 2022-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $33.24 | 2019-2020 | |
| Pfizer INC. | $31.67 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $28.82 | 2022-2023 | Qelbree |
| Genentech USA, INC. | $28.57 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $27.24 | 2022-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $26.06 | 2022 | |
| Amarin Pharma, INC. | $21.18 | 2019 | |
| Avanir Pharmaceuticals, INC. | $18.52 | 2022 | |
| Ardelyx, INC. | $17.68 | 2025 | Ibsrela |
| Collegium Pharmaceutical, INC. | $16.12 | 2025 | Jornay Pm |
| Lundbeck LLC | $15.96 | 2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.35 | 2023 | Xifaxan, Trulance |
| Abbvie INC. | $14.75 | 2025 | |
| Glaxosmithkline, LLC. | $14.39 | 2025 | Bexsero, Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $13.54 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurie Mickle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.